Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future

被引:0
|
作者
Calegari, M. A. [1 ]
Orlandi, A. [1 ]
Cocomazzi, A. [2 ]
Martini, M. [2 ]
Bagala, C. [1 ]
Indellicati, G. [1 ]
Zurlo, V. [1 ]
Monterisi, S. [1 ]
Di Dio, C. [1 ]
Barile, R. [1 ]
Di Salvatore, M. A. [1 ]
Basso, M. [1 ]
Cassano, A. [1 ]
Larocca, L. M. [2 ]
Barone, C. [3 ]
机构
[1] Univ Cattolica Sacro Cuore, Oncol Med, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Anat Patol, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy
关键词
D O I
10.1093/annonc/mdv233.164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P-164
引用
收藏
页数:1
相关论文
共 50 条
  • [21] FOLFIRINOX in Locally Advanced Pancreas Adenocarcinoma: Back to the Future?
    Bekaii-Saab, Tamos
    Goldberg, Richard M.
    ONCOLOGIST, 2013, 18 (05): : 487 - 489
  • [22] The prognostic and predictive role of class III b-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
    Sahin, T. K.
    Isik, A.
    Guven, D. C.
    Ceylan, F.
    Babaoglu, B.
    Akyol, A.
    Yalcin, S.
    Dizdar, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S906 - S906
  • [23] The prognostic and predictive role of class III b-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
    Sahin, T. K.
    Isik, A.
    Guven, D. C.
    Ceylan, F.
    Babaoglu, B.
    Akyol, A.
    Yalcin, S.
    Dizdar, O.
    PANCREATOLOGY, 2024, 24 (02) : 279 - 288
  • [24] Metformin upregulates hENT1 expression and enhances gemcitabine efficacy in pancreatic cancer cells
    Joseph, Stancy J.
    Osborne, Taylor
    Word, Beverly
    Lyn-Cook, Beverly
    CANCER RESEARCH, 2015, 75
  • [25] Adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunostaining in curative resected pancreatic adenocarcinoma: A biomaker stratified trial
    Shin, Dong Woo
    Kim, Min Jae
    Yang, Se Yeol
    Lee, Jong-Chan
    Hwang, Jin Hyeok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 47 - 47
  • [26] Adjuvant Gemcitabine Versus 5-Fluorouracil/Folinic Acid Based on hENT1 Immunostaining in Curative Resected Pancreatic Adenocarcinoma: A Biomaker Stratified Trial
    Shin, D. W.
    Kim, M. J.
    Lee, J. C.
    Kim, J.
    Hwang, J. H.
    PANCREAS, 2019, 48 (10) : 1523 - 1523
  • [27] Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
    Jordheim, Lars Petter
    Dumontet, Charles
    BIOMARKERS IN MEDICINE, 2013, 7 (04) : 663 - 671
  • [28] Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
    Greenhalf, William
    Ghaneh, Paula
    Neoptolemos, John P.
    Palmer, Daniel H.
    Cox, Trevor F.
    Lamb, Richard F.
    Garner, Elizabeth
    Campbell, Fiona
    Mackey, John R.
    Costello, Eithne
    Moore, Malcolm J.
    Valle, Juan W.
    McDonald, Alexander C.
    Carter, Ross
    Tebbutt, Niall C.
    Goldstein, David
    Shannon, Jennifer
    Dervenis, Christos
    Glimelius, Bengt
    Deakin, Mark
    Charnley, Richard M.
    Lacaine, Francois
    Scarfe, Andrew G.
    Middleton, Mark R.
    Anthoney, Alan
    Halloran, Christopher M.
    Mayerle, Julia
    Olah, Attila
    Jackson, Richard
    Rawcliffe, Charlotte L.
    Scarpa, Aldo
    Bassi, Claudio
    Buechler, Markus W.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (01):
  • [29] Adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunostaining in curative resected pancreatic adenocarcinoma: A biomaker stratified trial.
    Shin, Dong Woo
    Kim, Min Jae
    Yang, Se Yeol
    Lee, Jong-chan
    Hwang, Jin-Hyeok
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [30] Human Equilibrative Transporter 1 (hENT1) Expression is not Predictive for Gemcitabine Outcome in Patients With Advanced Biliary Tract Cancer
    Son, Jun Hyuk
    Jang, Dong Kee
    Lee, Jae Woo
    Park, Jin Myung
    Lee, Sang Hyub
    Ahn, Dong-Won
    Ryu, Ji Kon
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2016, 150 (04) : S515 - S515